Santaris Pharma A/S Report issue

For profit Phase 1 Phase 2
Founded: Horsholm Denmark (2003)
Status: Acquired by Roche (2014)

Organization Overview

First Clinical Trial
2005
NCT00285103
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (5)

miravirsen (6 trials)

ribavirin (virazole) (1 trial)

sodium chloride (4 trials)

spc2996 (1 trial)

telaprevir (incivek) (2 trials)

Drugs in Phase 1 Trials (2)

spc4955 (1 trial)

spc5001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Hypercholesterolemia (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 7